Prognostic factors analysis in patients with stage II bladder cancer
https://doi.org/10.17650/1726-9776-2008-4-2-31-35
Abstract
Purpose. Investigate prognostic solemnity of the clinical and laboratory values of the II stage bladder cancer patients and develop a nomogram allowing to predict a clinical outcome of this patient category.
Materials and methods. Data of 299 BC patients, being treated in oncology center named after N.N. Aleksandrov since 1995 to 2002 were analysed retrospectively. The patients with transitional cell BC T2N0M0 (UICC classification 2002) treated according to a radical program with the use of organ-sparing or organ-removal method were included in the study. The organ-sparing treatment was undergone by approximately 250 patients (83,6%), cystectomy — 49 (16,4%). Observation period median amounted 62 months. Risk ratio (HR) and confidence interval (CI) were calculated. The calculations were performed by program complex STATISTICA 6.0. The obtained values of the risk ratio were used to develop a nomogram.
Results. Main 5-year probability of survival of the II stage bladder cancer patients included in the study mounted 70,9 ± 2,8%. On basis of ratios obtained by multiple classification using multivariate regression model of the proportional risks of Kox, a nomogram of the prediction of the treatment results of the II stage bladder cancer patients was developed. A classification scale in what integer values in scores were awarded to gradations of the prognostic factors, is made. According to the given nomogram, a criterion can possess the value from 0 to 19 scores. The investigated body of 299 patients are distributed to 2 classes with the statistically significant discriminating long-term results of the treatment. 88 (29,4%) patients with the general 5-year probability of survival are attributed to unfavorable class, 211 (70,6%) patients with the probability of survival 82,1±2,8% — to the favorable counterpart.
About the Authors
V. U. Vasilevich
Center of oncology and medical radiology named after N.N. Aleksandrov
Belarus
Minsk
Belarus
Minsk
O. G. Sukonko
Center of oncology and medical radiology named after N.N. Aleksandrov
Belarus
Minsk
Belarus
Minsk
L. V. Mirilenko
Center of oncology and medical radiology named after N.N. Aleksandrov
Belarus
Minsk
Belarus
Minsk
A. I. Rolevich
Center of oncology and medical radiology named after N.N. Aleksandrov
Belarus
Minsk
Belarus
Minsk
References
1. Поляков С.М., Левин Л.Ф., Шебеко Н.Г. Злокачественные новообразования в Беларуси, 1996–2005 гг. Под ред. А.А. Граковича, И.В. Залуцкого. Минск, БелЦМТ; 2006.
2. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001. с. 2–5.
3. Fujii Y., Kawakami S., Koga F. et al. Longterm outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003;92:559–62.
4. Zieger K., Wolf H., Olsen P.R., Hojgaard K. Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression. BJU Int 2000;85:824–8.
5. Borhan A., Reeder J.E., O'Connell M.J. Grade progression and regression in recurrent urothelial cancer. J Urol 2003;169:2106–9.
6. Soloway M., Bruck D.S., Kim S.S. Expectant management of small recurrent, non-invasive papillary bladder tumours. J Urol 2003;170:438–41.
7. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186–90.
8. Sengupta S., Blute M.L. The management of superficial transitional cell carcinoma of the bladder. Urology 2006;67(3 Suppl1):48–54.
9. Gospodarowicz M. Radiotherapy and Organ Preservation in Bladder Cancer: Are We Ignoring the Evidence? J Clin Oncol 2002;14:3048–50.
10. Quek M.L., Stein J.P., Daneshmand S. et al. A critical analysis of perioperative mortality from radical cystectomy. J Urol 2006;175: 886–90.
11. Novotny V., Hakenberg O.W., Wiessner D. et al. Perioperative complication of radical cystectomy in a contemporary series. Eur Urol 2007; 51:397–402.
12. Michaelson M.D., Shipley W.U., Heney N.M. et al. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer 2004; 90:578–81.
13. Rosenberg J.E., Carroll P.R., Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol 2005;174:14–20.
14. Weizer A.Z., Joshi D., Daignault S. et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 2007;177:1287–93.
15. Sylvester R.J., van der Meijden A.P., Oosterlink W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–77.
16. Palou J. Patient risk profiles: prognostic factors of recurrence and progression. Eur Urol Suppl 2006;5:648-53.
17. Wazait H.D., Al-Bhueissi S.Z., Patel H.R. et al. Long-term surveillance of bladder tumours: current practice in the United Kingdom and Ireland. Eur Urol 2003;43:485-8.
18. Leibovitch L., Ben-Chaim J., Ramon J. et al. The significance of urethral obstruction in invasive transitional cell carcinoma of the urinary bladder. J Surg Oncol 1993;52:31.
19. Wallace A. Superficial bladder cancer. Comprehensive Urology. Ed. by R.M. Weiss, N.J.R. George, P.H. O’Reily; 2001. p. 363-73.
20. Tinzl M., Marberger M. Urinary Markers for Detecting Bladder Cancer. EAU Update Series 2003;1(2):64-70.
21. Satoh E., Miyao N., Tachiki H. Prediction of muscle invasion of bladder cancer by cystoscopy J. Urol 2002;41:178–81.
Review
For citations:
Vasilevich V.U., Sukonko O.G., Mirilenko L.V., Rolevich A.I. Prognostic factors analysis in patients with stage II bladder cancer. Cancer Urology. 2008;4(2):31-35. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-2-31-35
Views:
254
Email this article 